Ferriscan receives FDA approval
Friday, 28 January, 2005
Inner Vision Biometrics (IVB), a subsidiary of Perth based Resonance Health (ASX: RHT) has received FDA marketing approval for its novel diagnostic test for liver iron concentrations.
The FerriScan test non-invasively measures the iron content of the liver, and can be used to detect and treat iron overload disorders including thalassemia and hereditary haemochromatosis using specifically configured MRI machines. Scan data is analysed at a centralised IVB image processing centre using proprietary software.
FerriScan has already been approved for listing by the TGA and has received CE Mark approval in Europe, where partnerships with diagnostic imaging companies are already in place.
"We will be meeting with major US-based diagnostic imaging groups over the next several weeks to accelerate arrangements for the US commercial launch of the FerriScan test," said Resonance's executive director Tony Fitzgerald.
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...